Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey W Stephens

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Clinical Medicine (London, England)|December 2, 2010
The incretin system in the management of type 2 diabetes mellitusJeffrey W Stephens
Patient Preference and Adherence|April 3, 2010
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectivesMahamood Edavalath, Jeffrey W Stephens
Diabetes, Obesity & Metabolism|December 23, 2003
Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease riskPhilippa J Talmud, Jeffrey W Stephens
Expert Opinion on Pharmacotherapy|September 22, 2015
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetesDavid M Williams, Jeffrey W Stephens
Expert Opinion on Drug Safety|November 6, 2008
Exenatide and pancreatitis: an updateSteve C Bain, Jeffrey W Stephens
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 18, 2022
Awareness of Genetic Polymorphism in Drug Metabolizing Enzymes and Transporters May Promote Personalized Type 2 Diabetes Management [Response to Letter]David M Williams, Jeffrey W Stephens
Expert Opinion on Drug Safety|August 11, 2007
Safety and adverse effects associated with GLP-1 analoguesJeffrey W Stephens, Stephen C Bain
Expert Opinion on Drug Metabolism & Toxicology|February 16, 2016
Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetesRose Anderson, Jennifer Hayes, Jeffrey W Stephens
Drug Design, Development and Therapy|August 4, 2016
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyJennifer Hayes, Rosie Anderson, Jeffrey W Stephens
BMJ Case Reports|June 25, 2017
Obesity-related hypogonadism: a reversible conditionStamatios Zouras, Jeffrey W Stephens, David Price
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Clinical Medicine (London, England)|December 2, 2010
The incretin system in the management of type 2 diabetes mellitusJeffrey W Stephens
Patient Preference and Adherence|April 3, 2010
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectivesMahamood Edavalath, Jeffrey W Stephens
Diabetes, Obesity & Metabolism|December 23, 2003
Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease riskPhilippa J Talmud, Jeffrey W Stephens
Expert Opinion on Pharmacotherapy|September 22, 2015
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetesDavid M Williams, Jeffrey W Stephens
Expert Opinion on Drug Safety|November 6, 2008
Exenatide and pancreatitis: an updateSteve C Bain, Jeffrey W Stephens
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 18, 2022
Awareness of Genetic Polymorphism in Drug Metabolizing Enzymes and Transporters May Promote Personalized Type 2 Diabetes Management [Response to Letter]David M Williams, Jeffrey W Stephens
Expert Opinion on Drug Safety|August 11, 2007
Safety and adverse effects associated with GLP-1 analoguesJeffrey W Stephens, Stephen C Bain
Expert Opinion on Drug Metabolism & Toxicology|February 16, 2016
Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetesRose Anderson, Jennifer Hayes, Jeffrey W Stephens
Drug Design, Development and Therapy|August 4, 2016
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyJennifer Hayes, Rosie Anderson, Jeffrey W Stephens
BMJ Case Reports|June 25, 2017
Obesity-related hypogonadism: a reversible conditionStamatios Zouras, Jeffrey W Stephens, David Price
Pageof 13